Validation of ALZpath’s pTau217 Antibody at AD/PD™ 2026: A Benchmark for Blood-Based Alzheimer’s Diagnostics

Data Presented Across 29 Sessions Highlights Precision, Accessibility and Platform-Agnostic Adoption, Establishing pTau217 as a Leading Blood-Based Biomarker

CARLSBAD, Calif., March 17, 2026 /PRNewswire/ — ALZpath, Inc., a prominent entity in the field of blood test-based diagnostic solutions for Alzheimer’s disease, has announced the extensive use of its proprietary pTau217 antibody at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™). This widespread adoption underscores the antibody’s high diagnostic accuracy and specificity, solidifying pTau217’s status as a leading blood-based biomarker for Alzheimer’s disease and reaffirming its role as the preferred antibody for scalable, high-performance testing globally.

ALZpath’s pTau217 antibody serves as a validated and foundational element of accessible diagnostic solutions, having been selected by leading in-vitro diagnostic (IVD) companies for the development of blood-based assays. Its platform-agnostic design facilitates seamless integration across various laboratory infrastructures.

“Our collaboration with a robust ecosystem of assay developers and clinical providers aims to streamline the incorporation of pTau217 testing into routine medical practice, addressing the anticipated 152 million global cases of dementia among adults aged 65 and older by 2050,” stated Mike Banville, CEO of ALZpath. “The continuous innovation in assay sensitivity and specificity related to pTau217 promises earlier detection, more accurate staging, and enhanced monitoring of therapeutic responses, which is crucial in the evolving diagnostic landscape for Alzheimer’s disease.”

ALZpath’s pTau217 antibody will be highlighted through eight live sessions, as well as two in the product theatre, fifteen posters, and four symposiums.

“The breadth of data presented featuring pTau217 illustrates its increasing clinical utility as the gold standard among reliable and scalable blood-based biomarkers for Alzheimer’s disease,” remarked Henrik Zetterberg, MD, PhD. “Consistent performance across independent studies and assay platforms reinforces its value in enhancing diagnostic confidence and enabling precise patient identification. Robust biomarkers such as pTau217 will be essential in supporting optimized clinical trial design and ultimately improving patient outcomes.”

About ALZpath
ALZpath, Inc. is at the forefront of blood test-based diagnostic solutions for Alzheimer’s disease. Its proprietary pTau217 antibody is integral to many of the most advanced and widely available blood-based tests, transforming the detection, treatment, and monitoring of Alzheimer’s disease. Through strategic licensing agreements with global industry leaders and collaborations with esteemed laboratories, ALZpath empowers partners to provide accurate, scalable testing to clinicians and patients worldwide. The company’s innovations have garnered numerous industry accolades, including Time Magazine Best Inventions (2024), Fast Company Most Innovative Companies (2025), and BioTech Breakthrough “Diagnostic Innovation of the Year” (2025). For further information, visit ALZpath’s website and follow the company on LinkedIn, X, BlueSky, and Facebook.